A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

After VERVE-102 showed the ability to lower LDL-C and PCSK9 in the Heart-2 trial, the firm said it will advance the therapy to a Phase II study later this year.

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Shares of Verve Therapeutics VERV surged 26.4% on Monday and continue to soar today after the company announced positive initial data from an early-stage study of its investigational candidate, ...

Verve Therapeutics (VERV) announced initial data from the Heart-2 Phase 1b clinical trial of VERVE-102. The Heart-2 Phase 1b clinical trial is ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH ...

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, ...

Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...